Latest Share Chat

REMOVE ADS

Genedrive Regulatory News (GDR)

Genedrive Information

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes

Get Live Data

1.275 0.05 (4.08%)

Bid:

1.20

Ask:

1.35

Spread: 0.15 (12.50%)

Market Cap: £20.47m

Last checked at -

Intraday Genedrive Share Chart

REMOVE ADS

Investor presentation

10 Jun 2020 07:00

RNS Number : 4507P

Genedrive PLC

10 June 2020

genedrive plc

("genedrive" or the "Company")

Investor presentation

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.

The event will be held on Friday, 12 June 2020 at 2pm. Please register your interest at https://voxmarkets.brand.live/c/genedrive-plc.

genedrive plc	+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)	+44 (0)20 7418 8900
James Steel / Oliver Jackson

finnCap (Joint Broker)	+44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy	+44 (0)7980 541 893 / +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently launched a high throughput SARS-CoV-2 assay and has a Genedrive® Point of Care version of the assay in development, both based on Genedrive® PCR chemistry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAFLFIRRFIAIII

Date		Source	Headline
24th Aug 2018	7:00 am	RNS	Notice of GM
22nd Aug 2018	7:00 am	RNS	Board Appointment
8th Aug 2018	7:00 am	RNS	genedrive partners with FIND to evaluate HCV test
19th Jul 2018	7:00 am	RNS	Director/PDMR Shareholding
13th Jul 2018	7:00 am	RNS	Trading Update
29th Jun 2018	9:36 am	RNS	Total Voting Rights
27th Jun 2018	7:15 am	EQS	Hardman & Co Research: genedrive plc (GDR): Preventing hearing loss in newborns
20th Jun 2018	7:00 am	RNS	Grant for NHS point-of-care test
19th Jun 2018	11:18 am	RNS	Additional Listing of Shares
11th Jun 2018	9:25 am	RNS	Completion of Disposal
4th Jun 2018	4:47 pm	RNS	Result of General Meeting
17th May 2018	2:32 pm	RNS	Circular re Proposed Disposal
14th May 2018	5:39 pm	RNS	Proposed disposal for up to £1.9 million in cash
10th May 2018	11:39 am	RNS	Holding(s) in Company
18th Apr 2018	7:00 am	RNS	genedrive plc to Present at the UK Investor Show
12th Apr 2018	9:53 am	EQS	Hardman & Co Research: genedrive plc (GDR): Progressing commercialisation plans
10th Apr 2018	7:00 am	RNS	Publication of Genedrive Performance Data in Gut
9th Apr 2018	9:06 am	RNS	Directorate Change
4th Apr 2018	8:48 am	RNS	Director/PDMR Shareholding
3rd Apr 2018	7:00 am	RNS	Genedrive® Hepatitis C test in Asia Pacific
27th Mar 2018	7:00 am	RNS	genedrive signs distribution agreement for India
20th Mar 2018	3:40 pm	RNS	Holding(s) in Company
20th Mar 2018	7:00 am	RNS	Interim Results
13th Mar 2018	7:00 am	RNS	Commercial sales of Genedrive® HCV ID Kit begin
27th Feb 2018	7:00 am	RNS	genedrive Receives Funding for TB Test Development
14th Feb 2018	7:00 am	RNS	Notice of Results
18th Jan 2018	11:59 am	RNS	Hardman Res: Hep-C point-of-care test launched
17th Jan 2018	2:01 pm	RNS	Holding(s) in Company
17th Jan 2018	7:00 am	RNS	Trading update
16th Jan 2018	7:00 am	RNS	First Successful Field Evaluation of HCV Assay
13th Dec 2017	7:15 am	RNS	Hardman Research: Remodelled for growth
7th Dec 2017	4:28 pm	RNS	Director/PDMR Shareholding
29th Nov 2017	2:19 pm	RNS	Result of AGM
21st Nov 2017	7:00 am	RNS	genedrive plc awarded Innovate UK grant
17th Nov 2017	11:25 am	RNS	2017 Annual Report and AGM Notice
14th Nov 2017	7:00 am	RNS	Distribution agreement with Sysmex Asia Pacific
8th Nov 2017	1:31 pm	RNS	Directorate Change
6th Nov 2017	8:51 am	RNS	Holding(s) in Company
2nd Nov 2017	7:00 am	RNS	Distribution update for India
23rd Oct 2017	7:00 am	RNS	Launches Genedrive® Hepatitis C test in Africa
18th Oct 2017	7:00 am	RNS	Holding(s) in Company
17th Oct 2017	7:00 am	RNS	Preliminary Results
16th Oct 2017	7:00 am	RNS	Distribution Agreement
11th Oct 2017	7:00 am	RNS	Notice of Preliminary Results
22nd Sep 2017	9:42 am	RNS	Holding(s) in Company
11th Sep 2017	7:00 am	RNS	Genedrive HCV Kit received CE Marking
27th Jul 2017	7:00 am	RNS	$1.4m Funding from US Department of Defense
13th Jul 2017	7:00 am	RNS	Trading Update
11th Apr 2017	7:00 am	RNS	Hep C data presentation at EASL
5th Apr 2017	12:39 pm	RNS	Director/PDMR Shareholding - Replacement

Latest Share Chat

Genedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Intraday Genedrive Share Chart

Investor presentation

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending